Neuprozyme Therapeutics ApS: Financial statements 2019
CVR: 40010106
Source: annual report 2019, Danish Business Authority
01/07/2018 – 30/06/2019
Neuprozyme Therapeutics ApS (CVR 40010106) has filed annual accounts for 2019. In 2019, the company reported a gross profit of DKK -7,500 and a net result of DKK -7,500 compared with DKK 0 the year before. Equity in the 2019 report amounted to DKK 42,500. The solvency ratio was 81.9%.
- Gross Profit
- DKK -7,500
- Profit/Loss
- DKK -7,500
- Equity
- DKK 42,500
- Total Assets
- DKK 51,875
Official annual report
Screen every Danish company
Combine filters on financials, industry, geography, property and risk, and instantly see which companies match.
Try company screeningAbout Neuprozyme Therapeutics ApS
Neuprozyme Therapeutics ApS is a Danish company of the type Anpartsselskab based in Hørsholm, founded in 2018. The company is registered under the industry Fremstilling af andre organiske basiskemikalier. The management consists of John Pedersen. The board consists of John Pedersen and Lone Ballegaard Pedersen. The company is owned by LJP HOLDING ApS. According to the 2025 annual report, the company had an average of 0 employees. In 2025, the company reported a gross profit of DKK -27,482 and a net result of DKK -25,574 compared with DKK -24,871 the year before. Equity in the 2025 report amounted to DKK 82,360.